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Zusammenfassung
Hintergrund: Eine Irinotecan-basierte Zweitlinien-
Chemotherapie bei metastasiertem kolorektalem Karzi-
nom ist wirksam, kann jedoch bei ausgeprägter Leber-
funktionseinschränkung aufgrund fortgeschrittener
hepatischer Metastasierung kontraindiziert sein. Fallbe-
richt: Eine 57-jährige Patientin mit diffuser Lebermetasta-
sierung eines kolorektalen Karzinomes entwickelte unter
der Erstlinientherapie mit Capecitabin und Oxaliplatin
(XELOX) einen Krankheitsprogress. Aufgrund der ausge-
prägten Lebermetastasierung, einhergehend mit chroni-
scher Cholestase und Hyperbilirubinämie, war eine
Zweitlinientherapie mit Irinotecan jedoch kontraindiziert.
In dieser Situation leiteten wir eine kombinierte Behand-
lung mit Cetuximab und Bevacizumab ein. Ergebnisse:
Sowohl der Allgemeinzustand der Patientin als auch die
laborchemischen Parameter verbesserten sich unter The-
rapie rasch. Staging-Untersuchungen nach 8 Wochen er-
gaben den Befund einer partiellen Remission. Da die Bili-
rubinwerte zu diesem Zeitpunkt stabil im Bereich der
oberen Normgrenze lagen, konnte die Behandlung auf
eine Standardtherapie mit Irinotecan, 5-Fluorouracil, Fo-
linsäure und Bevacizumab umgestellt werden. Schluss-
folgerung: Eine kombinierte Antikörpertherapie beste-
hend aus Cetuximab und Bevacizumab kann als wirk-
same Therapieoption in Erwägung gezogen werden,
wenn eine Standardchemotherapie aufgrund einge-
schränkter Leberfunktion nicht appliziert werden darf.
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Summary
Background: Irinotecan-based second-line chemothera-
py of metastatic colorectal cancer (CRC) is effective, it
might, however, be contraindicated in cases of severe
liver dysfunction due to advanced liver metastases. Case
Report: A 57-year-old woman with diffuse CRC liver
metastases showed progressive disease on first-line
treatment with capecitabine and oxaliplatin (XELOX).
Chronic cholestasis and hyperbilirubinemia caused by
advanced liver involvement prohibited second-line treat-
ment with irinotecan-based chemotherapy. We initiated
combined antibody treatment with cetuximab and beva-
cizumab. Results: Clinical performance status as well as
laboratory parameters improved rapidly. Staging investi-
gations after 8 weeks revealed a partial remission. Since
bilirubin levels had returned to the upper limit of normal,
therapy could be changed to standard irinotecan, 5-fluo-
rouracil, folinic acid, and bevacizumab. Conclusion: Com-
bined treatment with cetuximab and bevacizumab may
be considered as an effective treatment option in pa-
tients who cannot be treated with standard chemo-
therapy regimens due to impaired liver metabolism of
cytotoxic substances.
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Introduction
Colorectal cancer (CRC) is among the leading causes of
death from cancer. It is estimated that approximately 50% of
CRC patients develop metastases and eventually die of the
disease [1]. Modern chemotherapy regimens for metastatic
CRC combine 5-fluorouracil (5-FU) and folinic acid (FA)
with irinotecan (Campto®, Pfizer Pharma GmbH, Karlsruhe,
Germany) or oxaliplatin (Eloxatin®, Sanofi-Aventis
Deutschland GmbH, Berlin, Germany). Infusional 5-FU, FA
plus irinotecan (FOLFIRI) as well as infusional 5-FU, FA
plus oxaliplatin (FOLFOX) achieve response rates of
49–62% and overall survival times of 16–20 months [2–4].
The vascular endothelial growth factor (VEGF) antibody be-
vacizumab (Avastin®, Roche Pharma AG, Grenzach-Wyhlen,
Germany) as well as the epidermal growth factor receptor
(EGFR) antibody cetuximab (Erbitux®, Merck Pharma
GmbH, Darmstadt, Germany) can further improve chemo-
therapy efficacy and have been approved in this setting
recently [5, 6]. Median survival times of the order of 20
months or above can, however, only be achieved if patients
are able to receive all three cytotoxic drugs in the course of
their disease [7]. This implies the presence of adequate liver
and bone marrow parameters during first- and further-line
treatment.
In CRC the liver is the most common organ of distant
metastases. Therefore, liver dysfunction as well as chronic
cholestasis with reduced hepatic and biliary excretion of var-
ious drug metabolites occur frequently in patients with
marked hepatic involvement. The primary objective of this
case report is to present an example of effective antineo-
plastic treatment despite severe liver dysfunction and hyper-
bilirubinemia.
Case Report
We will discuss the case of a 57-year-old female patient who was diag-
nosed with adenocarcinoma of the sigmoid colon in February 2006. She
presented with synchronous diffuse hepatic metastases at the time of ini-
tial diagnosis. After laparoscopic resection of the sigmoid, palliative
chemotherapy with capecitabine (Xeloda®, Roche Pharma AG) and ox-
aliplatin was started (XELOX). Staging investigations after 3 months of
chemotherapy revealed progressive disease.
The patient first presented to our oncology department in August 2006
with distinct jaundice, right upper abdominal pain, ascites, and peripheral
edema. Laboratory tests revealed marked elevation of liver parameters
(bilirubin: 12.8 mg/dl; alkaline phosphatase: 1,431 U/l; gamma-glutamyl
transferase, gamma-GT: 612 U/l; glutamic-pyruvic transaminase, GPT: 59
U/l; glutamic-oxalacetic transaminase, GOT: 380 U/l), lactate dehydroge-
nase of 1,741 U/l, and C-reactive protein of 19.9 mg/dl. Abdominal ultra-
sound as well as contrast-enhanced CT scans of the thorax and abdomen
showed diffuse hepatic metastases (liver involvement approximately
50%), massive ascites, lymph node enlargement up to 4 cm close to the
portal vein, and the beginnings of bilateral pleural effusion. There were
no signs of biliary tract obstruction with dilatation that could have been
treated by endoscopic or transhepatic biliary drainage. After the punc-
ture of 3,000 ml ascites and initiation of antibiotic treatment, the general
condition of our patient improved rapidly within a few days. 
We then started a combined antibody treatment with cetuximab and be-
vacizumab. The patient received cetuximab 400 mg/m2 (loading dose,
week 1) followed by 250 mg/m2 weekly combined with bevacizumab 5
mg/kg every other week. Two weeks after initiation of treatment, her
clinical performance status had improved dramatically, and treatment
could be continued on an outpatient basis. Bilirubin levels decreased to
4.4 mg/dl, 3.2 mg/dl, 1.7 mg/dl, and 1.0 mg/dl after 1, 2, 4, and 8 weeks,
respectively. Staging investigations including CT scans after 8 weeks of
treatment revealed a partial remission of hepatic metastases as well as
lymph node involvement. Only residual ascites was documented around
the gallbladder (fig. 1). The tumor marker carcinoembryonic antigen
(CEA) underlines the excellent response to the combined antibody
treatment, decreasing from 2,311 ng/ml before the start of treatment to
302 ng/ml and 69 ng/ml after 4 and 8 weeks. Since bilirubin levels had re-
mained stable <1.5 mg/dl over a period of 3 weeks by that time, we could
change treatment to FOLFIRI (irinotecan 180 mg/m2 as 90-minute i.v.
infusion, FA 400 mg/m2 as 2-hour i.v. infusion, 5-FU 400 mg/m2 as i.v.
bolus, 5-FU 2,400 mg/m2 as 46-hour continuous i.v. infusion) plus beva-
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Fig. 1. Computed tomography scans (coronal
and transversal images) of a patient with
advanced metastatic colorectal cancer. 
August 2006: Progressive disease after first-line
treatment with XELOX; liver involvement ap-
proximately 50%, ascites, and periportal lymph
node metastases; October 2006: staging investi-
gations after 8 weeks of combined treatment
with cetuximab plus bevacizumab showing a
partial remission; January 2007: staging investi-
gations after 12 weeks of further treatment
with FOLFIRI plus bevacizumab showing
stable disease.
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cizumab. We continued treatment on a biweekly schedule. Staging inves-
tigations after 5 cycles of FOLFIRI plus bevacizumab showed stable dis-
ease (fig. 1).
Altogether, our patient tolerated initial treatment with cetuximab plus
bevacizumab very well. She was able to resume work after only 3 weeks
of treatment. She suffered a maximum of grade 3 skin toxicity (sympto-
matic papulopustular rash affecting more than 50% of body surface) 3
weeks after the start of therapy. The rash improved rapidly to grade 1 skin
toxicity by tetracyclines administered orally in combination with topical
antiacne agents. She experienced no other clinically significant side
effects. Tolerance of FOLFIRI plus bevacizumab, however, was slightly
worse with grade 1 alopecia as well as grade 1 fatigue. Our patient is cur-
rently still on treatment with FOLFIRI plus bevacizumab.
Discussion
Second-line treatment with irinotecan-based chemotherapy
after failure of first-line oxaliplatin-based treatment (or vice
versa) is the current standard of care for patients suffering
from metastatic CRC. Even though response rates are very
modest in second-line setting, disease stabilization can again
be achieved in 34–63% of patients [8].
However, the metabolism of irinotecan is dependent on liver
function, particularly on bilirubin levels. Irinotecan is convert-
ed into its active metabolite SN-38 by carboxylesterase en-
zymes. SN-38 is further metabolized and inactivated through
conjugation into SN-38 glucuronide (SN-38-G) by uridine
diphosphate glucuronosyltransferase (UGT-1A1), the same
isoenzyme responsible for glucuronidation of bilirubin. Thus,
hyperbilirubinemia reflects deficiency of UGT-1A1 and leads
to significantly reduced clearance of irinotecan and SN-38.
Irinotecan clearance is decreased by approximately 40% with
bilirubin levels between 1.5 and 3× the upper limit of normal
(ULN), and dose reduction is recommended. Once bilirubin
levels exceed 3× ULN, application of irinotecan is contraindi-
cated [9, 10].
The EGFR antibody cetuximab achieves response rates of ap-
proximately 11% in second- and further-line treatment. How-
ever, in Europe it is only approved when combined with
irinotecan chemotherapy [5, 11]. Furthermore, there is no
clinical evidence of bevacizumab activity when applied as a
single substance [12]. Thus, there were no standard of care
treatment options for our patient, who presented to our de-
partment after the failure of oxaliplatin- and fluoropyrimi-
dine-based first-line treatment (XELOX) with severe liver
dysfunction causing marked hyperbilirubinemia >10 mg/dl
due to hepatic metastases and chronic cholestasis.
We decided to initiate combined antibody treatment with
bevacizumab and cetuximab. The chimeric IgG antibody
cetuximab and the humanized IgG antibody bevacizumab
follow a nonspecific elimination pathway, which is common
for all antibodies. They are recognized by cells of the reticu-
loendothelial system that display receptors with binding affin-
ity to the constant region of the antibody (Fc fragment). Anti-
bodies are degraded by internalization and further intracellu-
lar catabolism. Due to the very large number of receptors in
the body, this elimination process is nonsaturable at therapeu-
tic antibody levels, and it is not dependent on liver function
[13]. Therefore cetuximab and bevacizumab could be safely
applied at normal doses in our patient.
This combination was evaluated in a trial presented by Saltz
et al. at ASCO 2005 [14]. The phase II study randomized 81
patients with irinotecan-refractory metastatic CRC to either
cetuximab plus bevacizumab or cetuximab plus bevacizumab
plus irinotecan. Nearly 90% of patients had additionally re-
ceived prior oxaliplatin-based treatment. Even though patient
numbers were limited, response rates of this heavily pre-
treated patient population were promising. The purely bio-
logical treatment (cetuximab plus bevacizumab) achieved a
response rate of 23% and a disease control rate (partial remis-
sion + stable disease) of 77%. The combination of cetuximab,
bevacizumab, and irinotecan was even more effective (35%
partial response, 43% stable disease). Thus, the combination
of the EGFR antibody plus the VEGF antibody was the most
favorable treatment option we could propose to our patient.
Fortunately treatment efficacy was impressive, with a rapid
improvement of the clinical performance status and the ab-
normal liver function tests.
Since there is increasing evidence that skin rash can serve as a
surrogate marker for response to cetuximab treatment, the
fact that our patient developed grade 3 skin toxicity might re-
flect a particularly high sensitivity of her CRC tumor cells to
the anti-EGFR treatment strategy [5, 15]. After achieving a
partial remission (fig. 1) as well as stable bilirubin levels,
‘standard’ second-line treatment with FOLFIRI plus beva-
cizumab was no longer contraindicated.
Conclusion
We propose that combined treatment with cetuximab and
bevacizumab may be considered as an effective treatment
option in patients who cannot be treated with standard
chemotherapy regimens due to impaired metabolism of cyto-
toxic substances.
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